- Emergent Biosystems (NYSE:EBS) inks an agreement with GlaxoSmithKline (GSK) to acquire raxibacumab, a fully human monoclonal antibody for the treatment and prevention of inhaled anthrax, for $76M in upfront cash and up to $20M in milestones.
- EBS will also assume responsibility for a multiyear contract with BARDA to supply the product to the U.S. Strategic National Stockpile. The value of the contract is ~$130M. It will transfer manufacturing to its Baltimore, MD facilities sometime in 2020.
- Shares are off a fraction after hours on light volume.